Literature DB >> 14586135

IGF-1 induces growth, survival and morphological change of primary hepatocytes on a galactose-bared polymer through both MAPK and beta-catenin pathways.

Anup Kumer Kundu1, Masato Nagaoka, Ezharul Hoque Chowdhury, Shinichi Hirose, Tadashi Sasagawa, Toshihiro Akaike.   

Abstract

PVLA poly-(N-p-vinylbenzyl-O-beta-D-galactopyranosyl-D-gluconamide) is a glycopolymer composed of hydrophilic carbohydrate side chain and hydrophobic styrene polymer. The hydrophilic carbohydrate residue of PVLA can be recognized as a ligand for hepatocytes asialoglycoprotein receptor (ASGP-R), which is abundant on the hepatocyte cell surface. Adhering to the PVLA coated dishes, hepatocytes try to form aggregates that have a long time survival and also cells in these aggregates exhibit better maintenance of specific hepatocyte functions. Stimulation of the cells with IGF-1 in this culture condition results in the formation of lower aggregates. In addition to the morphological influences of IGF-1 to these cells, we have also found that IGF-1 transmits growth stimulatory responses to hepatocytes on PVLA through both mitogen activated protein kinase (MAPK) pathway and beta-catenin pathways. The phosphorylation of MAPK can take place within 5 min of stimulation with IGF-1 and within at least 10 ng/ml of IGF-1 concentration. Inhibition of MAPK activation by MEK-1 inhibitor PD98059 reduces IGF-1 induced MAPK phosphorylation, and also IGF-1 stimulated DNA synthesis. Similarly, the use of PI3-K inhibitor LY294002 also inhibits IGF-1 stimulated DNA synthesis. IGF-1 stimulation enhances the migration of beta-catenin from the cytoskeleton and cell membrane to the cytoplasm which also is the reason behind formation of spheroids and lower aggregates. IGF-1 stimulation also shows increased translocalization of beta-catenin to the nucleus that is essentially important to produce beta-catenin responsive effects to the cells. These studies thus suggest that IGF-1 can stimulate the growth and survival of hepatocytes on PVLA through both MAPK and beta-catenin signaling pathways, and that the activation of beta-catenin signaling pathway produces the morphological changes of IGF-1 induced cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586135     DOI: 10.1247/csf.28.255

Source DB:  PubMed          Journal:  Cell Struct Funct        ISSN: 0386-7196            Impact factor:   2.212


  5 in total

1.  Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis.

Authors:  Leander Blaas; Jan-Wilhelm Kornfeld; Daniel Schramek; Monica Musteanu; Gernot Zollner; Judith Gumhold; Franziska van Zijl; Doris Schneller; Harald Esterbauer; Gerda Egger; Markus Mair; Lukas Kenner; Wolfgang Mikulits; Robert Eferl; Richard Moriggl; Josef Penninger; Michael Trauner; Emilio Casanova
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

2.  Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice.

Authors:  Esteban J Fiore; Juan M Bayo; Mariana G Garcia; Mariana Malvicini; Rodrigo Lloyd; Flavia Piccioni; Manglio Rizzo; Estanislao Peixoto; M Beatriz Sola; Catalina Atorrasagasti; Laura Alaniz; María A Camilletti; Mónica Enguita; Jesús Prieto; Jorge B Aquino; Guillermo Mazzolini
Journal:  Stem Cells Dev       Date:  2014-12-03       Impact factor: 3.272

3.  Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice.

Authors:  Susan E Olivo-Marston; Stephen D Hursting; Jackie Lavigne; Susan N Perkins; Rami S Maarouf; Shoshana Yakar; Curtis C Harris
Journal:  Mol Carcinog       Date:  2009-12       Impact factor: 4.784

Review 4.  Weight control and cancer preventive mechanisms: role of insulin growth factor-1-mediated signaling pathways.

Authors:  Linglin Xie; Weiqun Wang
Journal:  Exp Biol Med (Maywood)       Date:  2013-02

5.  IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment.

Authors:  Daniela Diehl; Doris Oesterle; Martin W Elmlinger; Andreas Hoeflich; Eckhard Wolf; Harald Lahm
Journal:  J Carcinog       Date:  2006-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.